Effect of Butyric Acid on p53 Expression and Apoptosis in Colon Epithelial Cells in Mice after Treated with 9,10-dimethyl-1,2-benz(a)anthracene  by Siregar, Cherry et al.
 Procedia Chemistry  18 ( 2016 )  141 – 146 
1876-6196 © 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Peer-review under responsibility of the organizing committee of the Molecular and Cellular Life Sciences: Infectious Diseases, Biochemistry and 
Structural Biology 2015 (MCLS 2015)
doi: 10.1016/j.proche.2016.01.022 
Available online at www.sciencedirect.com
ScienceDirect
Molecular and Cellular Life Sciences: Infectious Diseases, Biochemistry and Structural Biology 
2015 Conference, MCLS 2015 
Effect of Butyric Acid on p53 Expression and Apoptosis in Colon 
Epithelial Cells in Mice after Treated with  
 9,10-dimethyl-1,2-benz(a)anthracene 
Cherry Siregara*, Eddy Bagus Wasitob, I Ketut Sudianac 
aClinical Microbiology Laboratory, Adam Malik Hospital, Medan 20136, Indonesia 
bMicrobiology Department, Faculty of Medicine Airlangga University, Surabaya 60115, Indonesia 
cAnatomical Pathology Department, Faculty of Medicine Airlangga University, Surabaya 60115, Indonesia 
Abstract 
As the most common  cancer, colorectal cancer is the fourth leading cause of death among this malignancy disease. Surgery 
procedure with chemotherapy and radiotherapy for colorectal cancer treatment may cause unpleasant side effects. Therefore,  
prevention and early detection of the disease is important. Butyrate, a short chain fatty acid, has a protective effect against colon 
cancer by inhibiting cell proliferation and inducing apoptosis. We conduct a research to investigate the effect of butyrate as a 
possible agent to decreased mutant p53 gene expression.  
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1. Introduction  
Colorectal cancer is one of the most common cancers worldwide, ranks fourth leading cause of death due to 
cancer1. The incidence of colorectal cancer in the United States is still high around more than 145.290 new cases 
with a mortality rate reached 56.290 in 2005 and is the second largest cause of death of all patients with cancer2. 
While in Indonesia, based on data from the Cancer Registration Bureau of the Department of Pathology, Faculty of 
Medicine, Airlangga University Surabaya, from 2002-2005, about 146 new cases of colorectal cancer were found3. 
The incidence of colon cancer in several cities in Indonesia as reported by Soetiarto was 5.5 per 100,000 in 
Yogyakarta  and in Ujung Pandang  up to 4.31 per 100,0004. 
Colorectal cancer associated with low fiber eating habits and several epidemiological studies reported that diets 
high in fat and protein and low in fiber is one of the risk factors for colon cancer6. Diets high in fiber turns correlated 
of concentration butyrate in providing a protective effect against rat colon carcinogenesis induced chemical 
carcinogens material as reported by McIntyre et al7. This underlies later studies focused on Short Chain Fatty Acid 
(SCFA) mainly butyrate which has a protective effect against colon cancer by inhibiting cell proliferation and 
inducing apoptosis8,9. 
Butyrate is a SCFA; the result of fermentation of carbohydrates by an-aerobic bacteria in the human colon10. 
Several in vitro studies have reported protective effect of butyrate on  colon cancer occur through inhibition of 
cell proliferation and induced cell apoptosis. Butyrate protective effect against colon cancer through its ability to 
inhibit the enzyme activity of histone deacetylase (HDAC) in the p21 gene locus (P21) that produce histone 
hyperacetylation mainly H3 and H4 cause transcriptional activation of P21 to halt the cell cycle9. 
P53 gene (P53), known as the “master guardian of the genome” is one of the tumor suppressor gene which 
regulates cell proliferation via activation of P21 and the control of cell apoptosis through activation of 
BAX11,12.  Under normal circumstances, the p53 protein will halt the cycle of cells with DNA damage so there is no 
cell proliferation but if there is a mutation in the p53 than cell cycle continues and the cells with DNA injury remain 
replicates producing cells with DNA damage11,12. 
However, the protective effect of butyrate against colon cancer via decreased expression of mutant p53 protein 
(P53) is not clearly known. If we do not know the mechanism of butyrate to decrease p53 mutant expression then the 
sustained P53 mutations will cause the cells undergo rapid and continuous proliferation and develop into cancer cells 
so cancer problem can not solved. 
Based on this set out the research is to prove the protective effect of butyrate against  expression of mutant P53 
protein mice in colonic epithelial cells and apoptosis of mice colon epithelial cells after DMBA induced.
2. Methods 
 
Carcinogenesis test material used is sodium butyrate (WAKO) and cancer induction material used is DMBA 
(9,10-dimethyl-1,2-benz(a)anthracene) from WAKO. This study uses laboratory mice (Mus musculus) Swiss 
Webster strain (Balb/c) 12-week-old male, weighing 25-35 g, housed at Experimental Animal Unit, Laboratory of 
Biochemistry, Faculty of Medicine, Airlangga University, Surabaya. 
In this true experimental study, male Swiss-Webster (Balb/c) Mus musculus (12 weeks old, weighing 25-35 g) 
divided in three groups of nine. No treatment applied to group one, group two received DMBA (10mg/100g body 
weight),  group three received butyrate (2.5 g/kg body weight for 14 days) and DMBA (10mg/100g body weight) on 
day 15. Mice sacrificed on day 20 to collect colonic tissues. Immunohistochemical staining and Tunel 
assay  performed for expression of mutant p53 and detect apoptotic colon epithelial cells, respectively. Normally and 
non-normally distributed data analyzed with one-way Anova with least significant difference test (Į=0.05) and 
Kruskal-Wallis with Mann-Whitney test (Į=0.05), respectively. 
3. Results and discussion 
3.1 Immunohistochemical examination of epithelial cells expressing mutant p53 in the colon of male Balb/c mice 
 
The results of counting the number of epithelial cells expressing mutant p53 in the colon of male Balb/c 
mice  seen in Table 1. Number of epithelial cells expressing mutant p53 in the colon of male Balb/c mice showed a 
significant difference (p < 0.0001; p < 0.05). Furthermore, the data  analyzed by Mann-Whitney test and showed a 
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significant difference in the value of the median number of colonic epithelial cells expressing mutant p53 between 
the treatment group that were not administered butyrate nor DMBA and the treatment group that were not 
administered butyrate but dosed with DMBA (p < 0.0001; p < 0.05); as well as in the treatment group without 
butyrate administration but dosed with DMBA  no significant difference with treatment group that administered 
butyrate and DMBA (p < 0.0001; p < 0.05). And there is no difference between treatment group that were not 
administered butyrate nor DMBA and the treatment group that administered butyrate and DMBA (p = 0.387; p > 
0.05). 
 
   Table 1. Median number of epithelial cells expressing mutant p53 in the colon male Balb/c mice 
Group Median (n=9) Min max p 
P1 ( no treatment ) 0 a 0 1  
P2 ( received DMBA) 3 b 2 5 < 0.0001 
P3 ( received butyrate ) 0 a 0 2  
   * a, b Different superscripts in the same column indicate significant differences (p < 0.0001) 
 
3.2 Results of examination on epithelial cells undergoing apoptosis in the colon of male Balb/c mice 
 
The results of counting the mean number of epithelial cells undergoing apoptosis in the colon of male Balb/c 
mice  seen in Table 2. Results on analysis the number of cells undergoing apoptosis using one way ANOVA test 
showed that there was no difference in the number of colonic epithelial cells undergoing apoptosis in all groups 
treatment (p = 0.129; p > 0.05). 
 
  Table 2. Mean number of epithelial cells undergoing apoptosis in the colon of male Balb/c mice 
Group Mean ± SD (n=9) min max p 
P1 ( no treatment ) 25.111 ± 31.362 0 95  
P2 ( received DMBA) 29.778 ± 33.082 3 97 0.129 
P3 ( received butyrate ) 77.444 ± 89.727 1 218  
 
3.3 Results of immunohistochemical staining and TUNEL assay 
 
The results of immunohistochemistry to detect mutant p53 expression of colonic epithelial cells of male Balb/c 
mice, using mutant p53 monoclonal antibodies with 400x magnification seen in Fig. 1. Image of the TUNEL assay 
staining to detect epithelial cells undergoing apoptosis in the colon of male mice Balb / c with 400x magnification, 




Fig. 1. Immunohistochemical staining (a) Colon slice of male Balb/c mice. P1=No treatment (400 X,  magnification ); (b) Colon slice of male 
Balb/c mice. P2= received DMBA (10mg/100g BW) (400 X,  magnification ), white arrow marked positive reaction (brown) ; (c) Colon slice of 
male Balb/c mice. P3= received butyrate (2.5g/kg BW) and DMBA (10mg/100g BW) (400 X,  magnification ) 
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Fig 2. Tunnel Assay Staining (a) Colon slice of male Balb/c mice. P1=No treatment (400 X,  magnification ), white arrow marked  apoptotic cell; 
(b) Colon slice of male Balb/c mice. P2= received DMBA (10mg/100g BW) (400 X,  magnification ), white arrow marked  apoptotic cell; (c) 
Colon slice of male Balb/c mice. P3= received butyrate(2.5g/kg BW) and DMBA (10mg/100g BW) (400 X,  magnification ), white arrow marked  
apoptotic cell 
 
Carcinogenesis is a process of development towards malignancy characterized by transform normal cells from the 
initiation and promotion stages up to the stage of progression that occurs after the cancer is formed13.  The main 
targets of genetic damage are three classes of regulatory gene; protooncogene that promote growth; tumor suppressor 
gene which inhibits the growth as well as gene that regulates programmed cell death or apoptosis11. 
P53 is a tumor suppressor gene that plays a role in cell cycle regulation and apoptosis by controlling a number of 
gene when DNA injury was occur14.  P53 role as a cell cycle regulator is through stop the cell cycle in G1 phase 
which caused by the increase transcription of p21 that would inhibition formation of cyclin-CDK complexes. Cell 
cycle arrest will allow time for DNA repair injury so the cell with injured DNA do not do replication and mitosis. 
Repair of cells with DNA injury occurs through activation of repair Growth Arrest and Damage45 (GADD45) gene 
which induced by P53. When DNA injury  repaired by the cell, P53 will increase transcription of MDM2 which then 
will suppress P53 so the cell cycle cessation eliminated. If the DNA injury is irreparable, P53 will direct the 
cell to eliminated by apoptosis11. Hence, P53 become target of the most frequent genetic changes in humans. More 
than 50% of human tumors contain mutations in the P5311. 
DMBA belongs to polycyclic aromatic hydrocarbon (PAH) procarsinogen group11,15. DMBA known 
as mutagenic16. DMBA metabolism forms 8,9-diol-10,11- epoxide which is highly reactive and can cause DNA 
injury. If a DNA injury occurs in P53 tumor suppressor gene,  it will form mutant p53. 
The results of immunohistochemical staining in this study show the number of colonic epithelial cells expressing 
mutant p53 in the treatment group without butyrate administration but dosed with  DMBA, more significant  than in 
the group of mice that were not administered butyrate nor DMBA (p < 0.0001; p < 0.05). This suggests that the 
DMBA is a mutagenic compound that causes P53 mutations in colonic epithelial cells. 
In this study, it turns out that the treatment group receiving DMBA without butyrate, were unable to cope with the 
DNA injury in P53 causing mutations of  P53, DNA repair mechanisms can not repair  injured DNA in P53  or 
through cell apoptosis. When cells with DNA injury stay in the cell cycle, there will be mutations and excessive gene 
expression continuously, causing uncontrolled cell proliferation. However, by  administration of butyrate, the 
number of colonic epithelial cells expressing mutant p53 in the group that receive butyrate and DMBA are 
significant fewer  than in the group that were not administered butyrate but dosed with DMBA (p < 0.0001; p < 
0.05). Ability cells to cope  the DNA injury in P53 by butyrate administration  gives the same result as in normal 
epithelium, it seen from the number of cells expressing mutant p53 in the group that administered butyrate and 
DMBA are not different from the treatment group that were not administered butyrate nor DMBA ( p = 0.387; p > 
0.05).  
Results showed that butyrate is able to inhibit mutant p53 expression in colonic epithelial cells induced DMBA. 
Butyrate is the end product of carbohydrate fermentation by anaerobic bacteria in the colon10. Butyrate concentration 
which emerges from the carbohydrate fermentation depends on the type of substrate available and colon microflora 
composition. Colon microflora that ferment carbohydrates producing butyrate are Clostridia, Fusobacteria, 
Eubacteria and Peptococci17. Butyrate has been studied for its role in nourishing the colonic mucosa and in the 
prevention of cancer of the colon, by promoting cell differentiation, cell-cycle arrest and apoptosis of transformed 
colonocytes; inhibiting the enzyme histone deacetylase18. Butyrate is a histone deacetylase inhibitors (HDACIs), a 
new class of anti-cancer drugs19,20. The results of this study support previous studies that butyrate can inhibit  mutant 
p53  expression in cell cultures derived from surgical specimens of patients with colon cancer21. 
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Apoptosis is a cell death through genetic mechanisms (destruction / fragmentation of chromosomes or DNA). 
Apoptosis can occur physiologically or pathologically12. Apoptosis is an important regulatory process to prevent 
cancer develop. Increasing number of cells undergoing apoptosis during the initiation phase of colon carcinogenesis 
is the result of  increasing the elimination cells with DNA injury (DNA defect) that can lead to malignancy. 
Butyrate can induce apoptosis in vitro in Caco-2 cells via mitochondrial pathway by activating  BAX 
proapoptotic gene and BCL-2 antiapoptotic gene barriers resulting in translocation cytochrome C from mitochondria 
to cytosol and then bind to Apopotic protease activating factor 1 (Apaf1) activating caspase cascade through caspase 
9 so that caspase 3 binds to DNAase breaking down DNA into fragments and apoptosis22. 
In this study, TUNEL assay used  for detect DNA fragmentation which is the characteristic of apoptosis. Result 
showed, no difference was found in the number of colonic epithelial cells undergoing apoptosis in all treatment 
groups (p = 0.129; p > 0.05), it was indicate that butyrate is able to inhibit mutant p53 the 
expression  in colonic epithelial cells induced by DMBA without increase in cell apoptosis. This is due to ability 
of cell to stop the cell cycle and allow time for the cell to repair DNA injury in P53 so the cell does not need 
to sacrificed to go through apoptosis. And apoptosis that occurs in this study is a physiological apoptosis, not the 
pathological apoptosis in response to DNA injury that can not repaired by the cell.  
These results do not support previous study as reported by Le-Leu et al who conducted research to assess the 
acute apoptotic response upon carcinogens material induction in mice23. Mice were fed a diet of three different kinds 
of carbohydrates (resistant starch, wheat bran, cellulose) for four weeks and then induced by Azoxymethane to cause 
DNA injury. The study results found that wheat bran increases faecal and colon butyrate concentration and increases 
apoptosis as response to carcinogenic materials induction in mice. Increased butyrate concentration positively 
correlated with the apoptotic index. Mastutik  also reported that administration of cellulose for 14 days in mice 
followed by DMBA would increase the number of colonic epithelial cells undergoing apoptosis24.  
The difference in this study result  due to butyrate dose given to mice at a dose of 2.5 g/kg body weight, can 
increase  GADD45 activity that plays a role in DNA repair mechanisms so that injuries  through the mechanism of 
DNA repair was occur, not through increased cell apoptosis to eliminate cells with DNA injury. Dose of 2.5g/kg 
body weight administered to the mice was 50% of the maximum dose (5g/kg) that given orally to mice29. Butyrate 
administration at 5g/kg orally to mice will reach butyrate plasma concentration of 9 mM (after 15 minutes of 
administration)25. Normal concentrations of butyrate in mice colon approximately 1-4 mm26. Ragione et al reported 
that butyrate is able to increase  GADD45 expression based on in vitro HT-29 cells which incubated with 2 mm 
sodium butyrate would increase GADD45 expression by 3 ± 4 times compared to no incubation with butyrate27. 
Chen et al reported that butyrate has the same ability with TSA to halt the cell cycle and induction of GADD45 in 
SW 620 human colon cancer cell line28. Dronmraju et al  also reported that in patients with colorectal cancer who 
were given resistant starch diet, a main substrate fermented by colon microflora producing butyrate; would 
increase GADD45 expression as much as two times higher than in those with no resistant starch in the diet (p = 
0.04)29. 
In this study it was found that administration butyrate at a dose of 2.5g/kg followed by 10mg/100g body 
weight DMBA induction, there was an increase in colonic epithelial cells undergoing apoptosis in the treatment 
group that were given butyrate and DMBA although after statistical analysis there was no difference among all 
treatment groups. Increasing number of cells undergoing apoptosis in the treatment group that were 
administered  butyrate and DMBA, probably cause by some cells undergoing DNA injury fail to be repaired by 
DNA repair so those cells would be eliminated through apoptosis (pathological apoptosis). This shows that apoptosis 
occurred in the treatment group that were given butyrate and DMBA is a physiological apoptosis and an increase in 
cells undergoing apoptosis in response to eliminate cells undergoing DNA injury (pathological apoptosis). This may 
explain the wide range between minimum and maximum result. So this study concluded that butyrate was able to 
inhibit the expression of mutant p53 mainly through the mechanism of DNA repair rather than through cell apoptosis 
mechanism, proved by fewer number of cells expressing mutant p53 in the treatment group that were 
administered butyrate and DMBA compared to treatment group that were not administered butyrate but dosed 
with DMBA (p < 0.0001) and there is no difference in the number of cells undergoing apoptosis in all treatment 
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4. Conclusion 
 
From the study results, it can be concluded that butyrate has a protective effect against colon carcinogenesis 
through inhibition against mutant p53 expression in the DMBA-induced colonic epithelial cells by DNA repair 
mechanism, and not through enhancement in colonic epithelial cell apoptosis due administration of DMBA. 
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